These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

97 related items for PubMed ID: 7139651

  • 1. Phase II trial of PALA in hypernephroma and urinary bladder cancer.
    Natale RB, Yagoda A, Kelsen DP, Gralla RJ, Watson RC.
    Cancer Treat Rep; 1982 Dec; 66(12):2091-2. PubMed ID: 7139651
    [No Abstract] [Full Text] [Related]

  • 2. Phase II study of PALA in advanced large bowel carcinoma.
    Rubin J, Purvis J, Britell JC, Hahn RG, Moertel CG, Schutt AJ.
    Cancer Treat Rep; 1981 Dec; 65(3-4):335-6. PubMed ID: 6453645
    [No Abstract] [Full Text] [Related]

  • 3. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in patients with non-small cell carcinoma of the lung.
    Casper ES, Gralla RJ, Kelsen DP, Houghton A, Golbey RB, Young CW.
    Cancer Treat Rep; 1980 Dec; 64(4-5):705-7. PubMed ID: 6448688
    [No Abstract] [Full Text] [Related]

  • 4. Phase II evaluation of N-(phosphonacetyl)-L-aspartic acid (PALA) in metastatic adenocarcinoma of the colon or rectum.
    Van Echo DA, Diggs CH, Scoltock M, Wiernik PH.
    Cancer Treat Rep; 1980 Dec; 64(2-3):339-42. PubMed ID: 7407767
    [Abstract] [Full Text] [Related]

  • 5. Phase II evaluation of N-(phosphonacetyl-L-aspartic acid (PALA) in patients with advanced colorectal carcinoma.
    Carroll DS, Gralla RJ, Kemeny NE.
    Cancer Treat Rep; 1980 Dec; 64(2-3):349-51. PubMed ID: 7407769
    [No Abstract] [Full Text] [Related]

  • 6. Phase II evaluation of PALA in patients with advanced head and neck cancer.
    Creagan ET, Nichols WC, O'Fallon JR.
    Cancer Treat Rep; 1981 Dec; 65(9-10):827-9. PubMed ID: 7273014
    [No Abstract] [Full Text] [Related]

  • 7. Phase II evaluation of PALA in patients with metastatic lung cancer.
    Creagan ET, Eagan RT, Fleming TR, Frytak S, Nichols WC, Ingle JN, Kvols LK.
    Cancer Treat Rep; 1981 Dec; 65(3-4):356-7. PubMed ID: 7237459
    [No Abstract] [Full Text] [Related]

  • 8. Phase II evaluation of PALA and AMSA for patients with disseminated malignant melanoma.
    Creagan ET, Ahmann DL, Ingle JN, Purvis JD, Green SJ.
    Cancer Treat Rep; 1981 Dec; 65(1-2):169. PubMed ID: 6894400
    [No Abstract] [Full Text] [Related]

  • 9. Phase II study of PALA and PCNU in the treatment of non-small cell lung cancer (EST 2580): an Eastern Cooperative Oncology Group study.
    Ettinger DS, Tritchler D, Earhart R, Creech RH.
    Cancer Treat Rep; 1984 Oct; 68(10):1297-8. PubMed ID: 6525602
    [No Abstract] [Full Text] [Related]

  • 10. Phase II trial of PALA in lymphoma: an Eastern Cooperative Oncology Group study.
    Muggia FM, Tsiatis AA, O'Connell MJ, Glick JH, Opfell RW, Coren A.
    Cancer Treat Rep; 1984 Mar; 68(3):551-3. PubMed ID: 6231103
    [Abstract] [Full Text] [Related]

  • 11. A phase II study of PALA (NSC 224131) in patients with advanced ovarian carcinoma. A Gynecologic Oncology Group study.
    Muss HB, Slavik M, Bundy B, Stehman FB, Creasman WT.
    Am J Clin Oncol; 1984 Jun; 7(3):257-60. PubMed ID: 6731346
    [Abstract] [Full Text] [Related]

  • 12. Biochemistry and clinical activity of N-(phosphonacetyl)-L-aspartate: a review.
    Grem JL, King SA, O'Dwyer PJ, Leyland-Jones B.
    Cancer Res; 1988 Aug 15; 48(16):4441-54. PubMed ID: 3293772
    [No Abstract] [Full Text] [Related]

  • 13. PALA (NSC-224131) in advanced carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group.
    Muss HB, Bundy B, DiSaia PJ, Stehman FB, Beecham J.
    Am J Clin Oncol; 1984 Dec 15; 7(6):741-4. PubMed ID: 6528869
    [Abstract] [Full Text] [Related]

  • 14. Sequential administration of thymidine, 5-fluorouracil, and PALA. A phase I-II study.
    Chiuten DF, Miller A, Valdivieso M, Loo TL, Bedikian A, Bodey GP, Benvenuto JA, Freireich EJ.
    Am J Clin Oncol; 1985 Aug 15; 8(4):332-5. PubMed ID: 4083263
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Application of biochemical modulation with a therapeutically inactive modulating agent in clinical trials of cancer chemotherapy.
    Martin DS, Stolfi RL, Sawyer RC, Young CW.
    Cancer Treat Rep; 1985 Apr 15; 69(4):421-3. PubMed ID: 3888389
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 5.